Alogliptin vs Sitagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Alogliptin · Nesina

Marketed by Takeda Pharmaceutical Company and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00286429 · Phase 3 · completed

The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.

Next expected readout: December 2026 · NCT07093476 (registry estimate)

Reported efficacy

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)

Result source: NCT02856113

Sitagliptin · Januvia

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00087516 · Phase 3 · completed

The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)

Result source: NCT00086502

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlogliptinSitagliptin
HbA1c, change-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
Body weight, change (kg)0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
HbA1c below 7%63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
Fasting plasma glucose, change-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
3-point MACE (% with event)11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708—Not posted · NCT01529541

HbA1c, change

Alogliptin
-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Sitagliptin
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854

Body weight, change (kg)

Alogliptin
0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
Sitagliptin
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854

HbA1c below 7%

Alogliptin
63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
Sitagliptin
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614

Fasting plasma glucose, change

Alogliptin
-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Sitagliptin
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614

3-point MACE (% with event)

Alogliptin
11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708
Sitagliptin
—Not posted · NCT01529541
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Alogliptin: 13 of 13 rows · Sitagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlogliptin
Rows use multiple source trials
Sitagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
show 3 more doses
-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted
-0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
-1.9 mmol/L @ 24wka,b,c
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-2.03 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.96 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
Glycemic Rescue
responder rate · % of participants
12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,d
NCT00328627 · Phase 3 · registry result, not featured evidence
show 7 more doses
14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wkc,d
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,b,c
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
show 3 more doses
-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-1.27% (n=183) @ 24wka,b,c
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-1.51% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.15% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
HbA1c Decrease 1 0
event count · % of participants
36.4% (n=129) vs 13.2% (n=129) placebo @ 26wk*25 mg QDa,e,c,f
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 47 participants as posted
show 1 more dose
31.3% (n=131) vs 13.2% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 41 participants as posted
38.6% (n=334) vs 43.9% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 129 Participants as posted
HbA1c Less Than 6 5
responder rate · % of participants
36.7% (n=90) vs 12.2% (n=90) placebo @ 16wka,c,g
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
show 2 more doses
21.4% (n=98) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
30% (n=60) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
20% (n=95) vs 22.2% (n=9) Metformin @ 54wkc,g
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,e,c,f
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted
show 1 more dose
51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted
36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted
HbA1c Less Than or Equal to 6.5
event count · % of participants
17.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QDa,e,c,f
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
show 1 more dose
19.7% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 42 participants as posted
16.2% (n=334) vs 25.2% (n=321) Oral Semaglutide @ 26wk*100 mge,c,f
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 54 Participants as posted
HOMA-B
absolute change · percentage points
15.02% (n=404) vs 2.057% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,f,h
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-41.15% (n=36) vs -1860.69% (n=5) Metformin @ 54wkc,f,h
NCT01485614 · Phase 3 · registry result, not featured evidence
PPG 2h Change mg/dL
absolute change · mmol/L
3.24 vs 3.39 Voglibose mmol/L @ 52wk*25 mg QDa,i,c,f
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 58.3 mg/dL as posted
show 7 more doses
3.35 vs 2.92 Voglibose mmol/L*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted
3.47 vs 3.39 Voglibose mmol/L @ 52wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 62.6 mg/dL as posted
3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted
2.88 vs 3.39 Voglibose mmol/L @ 52wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 51.8 mg/dL as posted
2.92 vs 2.92 Voglibose mmol/L*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted
3.65 vs 3.39 Voglibose mmol/L @ 52wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65.7 mg/dL as posted
3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted
-6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*i,c,f
NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted
Dropout rate
40.3%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
36.6%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.3%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
21.1%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
11%
NCT00968708 · Phase 3
14.9%
NCT01456130 · Phase 3 · registry result, not featured evidence
44.3%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
46.4%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.8%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
6.1%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
36.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
38.8%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
20.5%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
37.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
17.1%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
0%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
4.5%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
21.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
24.2%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
15.4%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.1%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.3%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
11.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
10.8%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
23.2%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
17.1%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
23.2%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
19.6%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
22.3%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
21.4%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
17.4%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
25.3%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
24.6%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1.9%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
5.7%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
2.6%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
6.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
3.8%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
3.8%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
6.3%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
28.9%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
27.3%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
31.1%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
74.6%100 mgk
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
67.6%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
69.1%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
67.6%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
9%
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
12.9%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
3%
NCT01131182 · Phase 4 · registry result, not featured evidence
20.5%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
10.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
2.5%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1%
NCT01485614 · Phase 3 · registry result, not featured evidence
4.8%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
10.6%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.6%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
4.7%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
0.8%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.3%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
5.6%
NCT00968708 · Phase 3
6%
NCT01456130 · Phase 3 · registry result, not featured evidence
8.4%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
6.8%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
1.1%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
2%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.2%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
7.4%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
3.6%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
6.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
4.5%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
—25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
—25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.6%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
1.5%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.1%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.8%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.8%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
3.7%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3.7%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
4.1%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
3.3%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
3%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
3.8%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
3.8%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
1.2%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
4.4%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
6.8%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
2.3%100 mgk
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
4.2%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
—
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—
NCT01131182 · Phase 4 · registry result, not featured evidence
7.9%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
3.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
—
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
—100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—
NCT01485614 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
0.5%
NCT03115112 · Phase 3 · registry result, not featured evidence
—
NCT02791490 · Phase 3 · registry result, not featured evidence
Serious AEs
5.4%25 mg QDj
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
6.1%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.8%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.7%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
33.6%
NCT00968708 · Phase 3
9%
NCT01456130 · Phase 3 · registry result, not featured evidence
11%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.9%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
2.2%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
0%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
1.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
16.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
16.7%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
0.9%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
3.6%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
1.9%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
8%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
13.6%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
4.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.6%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.3%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.6%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
4.9%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
0.6%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
6.5%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.5%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
3.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2.8%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
5.6%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
5.4%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
2%25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
3.4%25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
10.7%12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
4.9%12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
2.9%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
1.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
8.2%25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
7.9%12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
5.2%50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
2.1%6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.4%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
2.4%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
10%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
7.7%100 mgk
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
10.1%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
80%
NCT02556918 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
0%Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
0%Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02256189 · Phase 4 · registry result, not featured evidence
0%
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
3.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
2%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
3.7%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01131182 · Phase 4 · registry result, not featured evidence
3.1%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
4.7%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00686634 · Phase 4 · registry result, not featured evidence
2.7%
NCT00729326 · Phase 4 · registry result, not featured evidence
4.2%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
10.5%
NCT01485614 · Phase 3 · registry result, not featured evidence
6.5%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
6.7%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.1%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
25 mg QDj
urinary tract infection 7% (placebo 7.8%)
diarrhoea 6.2% (placebo 5.4%)
nasopharyngitis 6.2% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
12.5 mg QD
arthralgia 6.9% (placebo 2.3%)
urinary tract infection 6.1% (placebo 7.8%)
headache 5.3% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
25 mg QD
nasopharyngitis 7.6% (placebo 7.8%)
headache 6.8% (placebo 4.7%)
upper respiratory tract infection 4.5% (placebo 9.4%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
12.5 mg QD
nasopharyngitis 9% (placebo 7.8%)
headache 7.5% (placebo 4.7%)
back pain 5.3% (placebo 4.7%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
25 mg
headache 18.7% (placebo 10.5%)
hyperglycaemia 12% (placebo 11.8%)
diarrhoea 9.3% (placebo 9.2%)
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
renal impairment 7.5% (placebo 6.5%)
hypertension 7.1% (placebo 7.4%)
hypoglycaemia 6.2% (placebo 5.9%)
NCT00968708 · Phase 3
nasopharyngitis 35.8%
upper respiratory tract inflammation 11.9%
arthralgia 7.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
25 mg
upper respiratory tract infection 10.3%
hypertension 7.6%
nasopharyngitis 7.6%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
12.5 mg
upper respiratory tract infection 9.6%
nasopharyngitis 8.9%
diarrhoea 6.9%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 6.5% (placebo 1.1%)
upper respiratory tract infection 5.4% (placebo 3.3%)
blood triglycerides increased 2.2% (placebo 1.1%)
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
upper respiratory tract infection 3% (placebo 3.3%)
blood triglycerides increased 2% (placebo 1.1%)
urinary tract infection 2% (placebo 6.5%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 21.3% (placebo 1.1%)
urinary tract infection 6.6% (placebo 6.5%)
upper respiratory tract infection 3.3% (placebo 3.3%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
25 mg
hypertension 14.5%
urinary tract infection 11.7%
nasopharyngitis 11.6%
NCT00306384 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertension 14.8%
upper respiratory tract infection 11.6%
urinary tract infection 11.1%
NCT00306384 · Phase 3 · registry result, not featured evidence
25 mg QD
hyperglycaemia 17% (placebo 26.4%)
nasopharyngitis 6.3% (placebo 1.9%)
headache 5.4% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
12.5 mg BID
hyperglycaemia 11.8% (placebo 26.4%)
headache 4.5% (placebo 2.8%)
creatinine renal clearance decreased 3.6% (placebo 3.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
alogliptin 12.5 mg BID + metformin 1000 mg BID
creatinine renal clearance decreased 7.9% (placebo 3.8%)
diarrhoea 7% (placebo 2.8%)
dyspepsia 7% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
alogliptin 12.5 mg BID + metformin 500 mg BID
hyperglycaemia 7.5% (placebo 26.4%)
upper respiratory tract infection 7.5% (placebo 2.8%)
headache 6.6% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 20% (placebo 4.2%)
anaemia 12% (placebo 4.2%)
constipation 8% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence
25 mg QD + 30 mg QD
hypoglycaemia 13.6% (placebo 0%)
nasopharyngitis 13.6% (placebo 4.2%)
constipation 9.1% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
upper respiratory tract infection 7.2%
nasopharyngitis 6.9%
hypertension 5.9%
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 7% (placebo 4.7%)
upper respiratory tract infection 6.2% (placebo 3.9%)
abdominal pain upper 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertriglyceridaemia 5.5% (placebo 2.3%)
hypertension 4.7% (placebo 3.1%)
urinary tract infection 4.7% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence
25 mg + 15 mg
influenza 6.2% (placebo 2.3%)
nasopharyngitis 6.2% (placebo 3.9%)
oedema peripheral 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 30 mg
nasopharyngitis 6.9% (placebo 3.9%)
back pain 6.2% (placebo 3.9%)
influenza 6.2% (placebo 2.3%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 45 mg
diarrhoea 5.4% (placebo 8.5%)
headache 4.6% (placebo 4.7%)
oedema peripheral 4.6% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 15 mg
hypertension 6.9% (placebo 3.1%)
nasopharyngitis 6.2% (placebo 3.9%)
dizziness 5.4% (placebo 3.1%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
dizziness 3.8% (placebo 3.1%)
nasopharyngitis 3.8% (placebo 3.9%)
upper respiratory tract infection 3.8% (placebo 3.9%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 45 mg
back pain 9.2% (placebo 3.9%)
dizziness 4.6% (placebo 3.1%)
headache 4.6% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 6.7%
urinary tract infection 3%
oedema peripheral 1.2%
NCT00395512 · Phase 3 · registry result, not featured evidence
25 mg + 30 mg
headache 12.2%
back pain 6.1%
urinary tract infection 5.5%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
headache 8.6%
urinary tract infection 3.7%
back pain 1.8%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 7% (placebo 6.2%)
influenza 5.5% (placebo 4.1%)
oedema peripheral 5.5% (placebo 7.2%)
NCT00286494 · Phase 3 · registry result, not featured evidence
12.5 mg QD
oedema peripheral 6.1% (placebo 7.2%)
upper respiratory tract infection 5.6% (placebo 5.2%)
nausea 4.5% (placebo 2.1%)
NCT00286494 · Phase 3 · registry result, not featured evidence
25 mg QD
diarrhoea 3.4% (placebo 5.8%)
nasopharyngitis 3.4% (placebo 5.8%)
bronchitis 2.9% (placebo 1.9%)
NCT00286442 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 6.6% (placebo 3.8%)
nasopharyngitis 5.6% (placebo 5.8%)
upper respiratory tract infection 4.7% (placebo 6.7%)
NCT00286442 · Phase 3 · registry result, not featured evidence
25 mg QD
headache 5.6% (placebo 3%)
hypertension 5.6% (placebo 2%)
urinary tract infection 5.1% (placebo 3%)
NCT00286468 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 4.4% (placebo 3%)
diarrhoea 3.9% (placebo 0%)
hypertriglyceridaemia 3.9% (placebo 2%)
NCT00286468 · Phase 3 · registry result, not featured evidence
25 mg QD and 1-6 mg QD or BID
nasopharyngitis 37.5%
upper respiratory tract inflammation 10.5%
fall 7.9%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 36.6%
diabetic retinopathy 6.9%
constipation 5.5%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 1-6 mg QD or BID
nasopharyngitis 30.7%
upper respiratory tract inflammation 6.7%
back pain 5.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 31%
back pain 6.3%
headache 6.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 19.2%
upper respiratory tract inflammation 11.5%
back pain 3.8%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 19%
gastroenteritis 3.8%
upper respiratory tract inflammation 1.9%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 25 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 28.6%
back pain 5.7%
arthralgia 4.8%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 35.2%
upper respiratory tract inflammation 11.1%
back pain 7.4%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 11.5%
blood creatine phosphokinase increased 3.5%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 4.5%
blood creatine phosphokinase increased 0%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 22.4%
eczema 1.3%
NCT01263483 · Phase 2/3 · registry result, not featured evidence
25 mg QD + 0.2 mg TID
nasopharyngitis 16.5%
eczema 0%
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 33%
headache 7.2%
upper respiratory tract inflammation 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 28.7%
bronchitis 5.9%
back pain 5%
NCT01263496 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 35.1%
blood creatine phosphokinase increased 8.2%
back pain 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 30.2%
upper respiratory tract inflammation 8.3%
back pain 7.3%
NCT01263496 · Phase 2 · registry result, not featured evidence
25 mg QD
nasopharyngitis 12.5% (placebo 6.7%)
headache 6.3% (placebo 5.3%)
abdominal distension 3.8% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 8.3% (placebo 6.7%)
flatulence 4.8% (placebo 2.7%)
urticaria 3.6% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 10.1% (placebo 6.7%)
blood creatine phosphokinase increased 5.1% (placebo 2.7%)
abdominal distension 2.5% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 6.3% (placebo 6.7%)
bronchitis 3.8% (placebo 1.3%)
flatulence 2.5% (placebo 2.7%)
NCT01263470 · Phase 2 · registry result, not featured evidence
25 mg QD
headache 8.9% (placebo 7.3%)
abdominal pain upper 6.7% (placebo 0%)
dizziness 6.7% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
12.5 mg QD
rash 9.1% (placebo 2.4%)
abdominal pain 4.5% (placebo 0%)
arthralgia 4.5% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
100 mg QD
nausea 11.4% (placebo 0%)
headache 9.1% (placebo 7.3%)
urinary tract infection 9.1% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
50 mg QD
diarrhoea 7% (placebo 7.3%)
headache 7% (placebo 7.3%)
urinary tract infection 7% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
6.25 mg QD
urinary tract infection 7.1% (placebo 9.8%)
abdominal pain upper 4.8% (placebo 0%)
dizziness 4.8% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
25 mg
rash papular 25%
abdominal pain 0%
blood creatine phosphokinase increased 0%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
blood creatine phosphokinase increased 14.3%
haematocrit decreased 14.3%
haemoglobin decreased 14.3%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
headache 18.2%
fatigue 9.1%
nausea 9.1%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
diarrhoea 20%
neutrophil count decreased 20%
pyrexia 20%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
abdominal pain 25%
gastritis 12.5%
headache 12.5%
NCT00957268 · Phase 1 · registry result, not featured evidence
headache 30%
nausea 20%
constipation 10%
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
nausea 50%
diarrhoea 40%
vomiting 30%
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
100 mgk
upper respiratory tract infection 13.1%
dizziness 11.5%
nasopharyngitis 9.2%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 30 more results
100 mg/100 mg
upper respiratory tract infection 15.1%
dizziness 10.5%
nasopharyngitis 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg
upper respiratory tract infection 11.4%
arthralgia 9.8%
blood glucose increased 8.9%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg/200 mg
upper respiratory tract infection 16.4%
dizziness 12.4%
influenza 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
infection 2% (placebo 2%)
headache 1% (placebo 1%)
loss of appetite 1% (placebo 0%)
NCT02556918 · Phase 4 · registry result, not featured evidence
100 mg
headache 1.6%
hypertension 1.6%
diarrhoea 0%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 15.8%
arrhythmic events 5.3%
genital infection 5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
light-headedness 7.7% (placebo 7.7%)
paresthesias 7.7% (placebo 0%)
nausea 0% (placebo 7.7%)
NCT02639637 · Phase 4 · registry result, not featured evidence
light-headedness 0% (placebo 7.7%)
nausea 0% (placebo 7.7%)
paresthesias 0% (placebo 0%)
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
rash 0% (placebo 2.8%)
NCT01859793 · Phase 4 · registry result, not featured evidence
hypoglycemia 0%
NCT02312063 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
50 mg
erythema 38.5%
hypoglycaemia 7.7%
periodontitis 7.7%
NCT02318693 · Phase 4 · registry result, not featured evidence
diarrhoea 9.3%
nausea 7.8%
upper respiratory tract infection 6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
hypoglycaemia 14%
blood glucose decreased 6%
NCT01686932 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
hyperglycemia 11.1%
pressure ulcer/skin ulcer 11.1%
hypoglycemia 3.7%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
hypoglycemia 6.9%
pneumonia 6.9%
urinary tract infection 6.9%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
headache 4.9%
dizziness 3.9%
hyperhidrosis 3.7%
NCT01131182 · Phase 4 · registry result, not featured evidence
nausea 15.7%
vomiting 10.2%
nasopharyngitis 8.7%
NCT00870194 · Phase 4 · registry result, not featured evidence
nausea 10.2%
nasopharyngitis 7.8%
headache 7%
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
nausea 37%
vomiting 20.5%
headache 12.3%
NCT00729326 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 7.8%
diarrhoea 4.5%
nausea 3.9%
NCT04017832 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.8%
nasopharyngitis 15.8%
upper respiratory tract infection 12.6%
NCT01485614 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.1%
upper respiratory tract infection 14.5%
diarrhoea 11.3%
NCT01760447 · Phase 3 · registry result, not featured evidence
hypoglycaemia 20%
upper respiratory tract infection 11.1%
abdominal pain 8.9%
NCT01760447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13%
hypoglycemia 5.2%
influenza 5.2%
NCT03115112 · Phase 3 · registry result, not featured evidence
diarrhoea 7.9% (placebo 4.8%)
NCT02791490 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. eThe reported result categories differ.
  6. fTreatment context has not been resolved for both arms.
  7. gAssessment timepoints differ: 54 weeks versus 16 weeks.
  8. hAssessment timepoints differ: 54 weeks versus 52 weeks.
  9. iTrial phases differ: Phase 4 versus Phase 2.
  10. jPopulation comparability has not been reviewed for 65 of these studies.
  11. kPopulation comparability has not been reviewed for 33 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alogliptin

Rescue 19.5% (n=128) vs 40.3% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 25 participants as posted
show 5 more results
9% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 18 participants as posted
15.7% (n=198) vs 28.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 31 participants as posted
20.6% (n=131) vs 40.3% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
9.7% (n=196) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
14.9% (n=201) vs 28.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 30 participants as posted
HbA1c 6.5 or Less 2.3% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
show 7 more results
20.6% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
20.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
14.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
2.3% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
17.3% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
17.3% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 34 participants as posted
9.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
HbA1c 7.0 or Less 7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted
show 7 more results
44.3% (n=131) vs 23.4% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 58 participants as posted
49.2% (n=199) vs 34% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 98 participants as posted
34.8% (n=198) vs 18.2% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 69 participants as posted
8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
47.4% (n=133) vs 23.4% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 63 participants as posted
44.2% (n=197) vs 34% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
29.6% (n=203) vs 18.2% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 60 participants as posted
HbA1c 7 5 or Less 25.6% (n=129) vs 3.9% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 33 participants as posted
show 7 more results
67.2% (n=131) vs 39.1% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 participants as posted
70.9% (n=199) vs 48.5% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 141 participants as posted
56.6% (n=198) vs 33.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 112 participants as posted
16.8% (n=131) vs 3.9% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
60.9% (n=133) vs 39.1% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 81 participants as posted
64.5% (n=197) vs 48.5% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 127 participants as posted
46.3% (n=203) vs 33.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 94 participants as posted
HbA1c Decrease 0.5 54.3% (n=129) vs 31% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
show 9 more results
55% (n=131) vs 29.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 72 participants as posted
64.3% (n=199) vs 26.8% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 128 participants as posted
58.9% (n=207) vs 26.9% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 122 participants as posted
50.5% (n=198) vs 26.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 100 participants as posted
53.4% (n=131) vs 31% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
50.4% (n=133) vs 29.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 67 participants as posted
59.9% (n=197) vs 26.8% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 118 participants as posted
57.7% (n=213) vs 26.9% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 123 participants as posted
47.3% (n=203) vs 26.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 96 participants as posted
HbA1c Decrease 1 5 17.8% (n=129) vs 4.7% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
show 9 more results
12.2% (n=131) vs 4.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 16 participants as posted
18.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 37 participants as posted
11.6% (n=207) vs 5.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
12.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
16.8% (n=131) vs 4.7% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
8.3% (n=133) vs 4.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
16.2% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
9.4% (n=213) vs 5.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 20 participants as posted
6.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 13 participants as posted
HbA1c Decrease 2 0 8.5% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
show 9 more results
4.6% (n=131) vs 1.6% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 6 participants as posted
7% (n=199) vs 3.1% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 14 participants as posted
2.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
6.1% (n=198) vs 4% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
8.4% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
2.3% (n=133) vs 1.6% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
6.1% (n=197) vs 3.1% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
3.3% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 7 participants as posted
2.5% (n=203) vs 4% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
MACE 3-point Composite 11.3% (n=2701) vs 11.8% (n=2679) placebo
event count · % of participants
NCT00968708 · Phase 3
MACE Composite 12.7% (n=2701) vs 13.4% (n=2679) placebo
responder rate · % of participants
NCT00968708 · Phase 3
HbA1c Less Than 6 5 28.4% (n=67) @ 52wk
responder rate · % of participants
No placebo or comparator arm
HbA1c of < 6.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
Fasting Glucose Change mg/dL -0.58 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT01456130 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.5 mg/dL as posted
HbA1c Less Than or Equal to 6.5 11.6% (n=164) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg
responder rate · % of participants
NCT00395512 · Phase 3 · registry result, not featured evidence
show 10 more results
26.2% (n=878) vs 24.8% (n=869) Glipizide @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.8% (n=878) vs 20.8% (n=869) Glipizide @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
26.4% (n=878) vs 21.8% (n=869) Glipizide @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.1% (n=878) vs 19% (n=869) Glipizide @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
27.4% (n=164) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25.6% (n=873) vs 24.8% (n=869) Glipizide @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=873) vs 20.8% (n=869) Glipizide @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.2% (n=873) vs 21.8% (n=869) Glipizide @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
23.5% (n=873) vs 19% (n=869) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
26.4% (n=163) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination

+ 50 further endpoints in the CSV export.

Sitagliptin

PMG 2-hr Change mg/dL -48.9 vs -2.2 placebo mg/dL @ 24wk100 mg
absolute change · mg/dL
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-56.3 vs -2.2 placebo mg/dL @ 24wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 Metformin mg/dL @ 20wk
NCT01485614 · Phase 3 · registry result, not featured evidence
-1.7 vs -39.7 Metformin mg/dL @ 54wk
NCT01485614 · Phase 3 · registry result, not featured evidence
PMG 2-hr Change mg/dL -30.5 mg/dL @ 104wk100 mg/100 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-38.3 mg/dL @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-41.5 mg/dL @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-35.5 mg/dL @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hyperglycemia 83.5% (n=91) vs 74.7% (n=91) placebo @ 0.29wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 76 Participants as posted
show 1 more result
5.5% (n=91) vs 3.3% (n=91) placebo @ 0.29wk*
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
Persistent Hyperglycemia 63.7% (n=91) vs 64.8% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 58 Participants as posted
Glucose 148.7 vs 149.8 placebo mmol/L @ 0.29wk
absolute value · mmol/L
NCT02556918 · Phase 4 · registry result, not featured evidence
show 2 more results
154.2 vs 156.5 placebo mmol/L @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
9.5 vs 9.4 Basal Bolus mmol/L
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Hyperglycemia Ge 300 mg/dL 22% (n=91) vs 13.2% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
Severe Hypoglycemia Event Incidence 0% vs 0% placebo @ 0.29wk
event rate · count
NCT02556918 · Phase 4 · registry result, not featured evidence
show 1 more result
0% vs 0% placebo @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min -0.53 vs 0.67 Canagliflozin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Canagliflozin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence
FMD 5.8% (n=30) vs 6% (n=30) placebo @ 8wk
absolute change · percentage points
Following 8 weeks of therapy
NCT01859793 · Phase 4 · registry result, not featured evidence
Time in Tight Range 30.7% (n=138) vs 29.7% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Time in Range 57% (n=138) vs 59.6% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
36% (n=27) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
43% (n=29) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination

+ 62 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Sitagliptin's landscape